Table 2. Risk of Cancers for Members of Families That Fulfilled Amsterdam II Criteria.
| Cancer Site | SMR (95% CI) | |||
|---|---|---|---|---|
| Proband | First-Degree | Second-Degree | First-Cousin | |
| Esophagus | 1.60 (0.04-8.90) | 1.06 (0.39-2.32) | 0.64 (0.26-1.32) | 0.81 (0.47-1.30) |
| Stomach | 2.05 (0.42-5.98) | 2.90 (2.02-4.03) | 2.40 (1.80-3.14) | 1.66 (1.31-2.07) |
| Small intestine | NAa | 7.72 (5.17-11.08) | 5.10 (3.62-6.97) | 1.65 (1.05-2.48) |
| Colorectum | NAa | 10.10 (9.43-10.81) | 4.31 (3.98-4.65) | 1.85 (1.70-2.00) |
| Colon | NAa | 10.50 (9.67-11.34) | 4.28 (3.89-4.69) | 1.79 (1.62-1.98) |
| Rectum | NAa | 9.08 (7.94-10.34) | 4.33 (3.76-4.97) | 2.03 (1.76-2.34) |
| Liver | 0 | 3.34 (1.80-5.79) | 2.49 (1.52-3.84) | 1.14 (0.65-1.85) |
| Pancreas | 0.43 (0.011-2.39) | 1.44 (0.95-2.09) | 1.78 (1.36-2.29) | 1.55 (1.28-1.87) |
| Lung | 1.01 (0.41-2.08) | 1.058 (0.80-1.35) | 1.43 (1.21-1.68) | 1.29 (1.15-1.45) |
| Breast | 1.37 (0.88-2.04) | 1.67 (1.45-1.90) | 1.34 (1.20-1.49) | 1.28 (1.19-1.39) |
| Melanoma | 1.99 (1.06-3.40) | 1.69 (1.37-2.05) | 1.52 (1.32-1.74) | 1.45 (1.30-1.63) |
| Endometrium | NAa | 5.89 (5.09-6.78) | 2.70 (2.30-3.14) | 1.50 (1.29-1.73) |
| Ovary | 22.92 (17.12-30.06) | 4.78 (3.79-5.94) | 2.35 (1.85-2.95) | 1.59 (1.29-1.93) |
| Prostate | 1.96 (1.35-2.75) | 1.94 (1.73-2.17) | 1.77 (1.62-1.93) | 1.47 (1.37-1.57) |
| Kidney | 7.57 (4.33-12.29) | 3.22 (2.45-4.16) | 2.10 (1.66-2.62) | 1.53 (1.25-1.86) |
| Urinary bladder | 2.12 (0.92-4.17) | 1.62 (1.22-2.12) | 1.64 (1.32-2.00) | 1.35 (1.16-1.57) |
| Brain | 51.13 (39.46-65.17) | 7.63 (6.11-9.41) | 3.10 (2.48-3.84) | 1.07 (0.78-1.44) |
| Thyroid | 2.58 (0.70-6.59) | 2.26 (1.55-3.17) | 2.01 (1.61-2.48) | 1.34 (1.03-1.72) |
| Non-Hodgkin lymphoma | 2.20 (1.01-4.17) | 2.10 (1.64-2.65) | 1.19 (0.95-1.48) | 1.13 (0.95-1.33) |
| Myeloma | 0 | 0.77 (0.35-1.47) | 1.29 (0.85-1.88) | 1.24 (0.94-1.62) |
| Leukemia | 1.72 (0.56-4.02) | 1.42 (1.00-1.98) | 1.60 (1.27-1.99) | 1.51 (1.27-1.79) |
Abbreviations: NA, not applicable; SMR, standardized morbidity ratio.
a
No risk estimates can be computed for cancer sites in probands that are part of central definition of Amsterdam II criteria.